Clinical Report: Utilizing Patient-Derived Tumor Organoids for Tailored Cancer Treatment

Overview

This study evaluates the potential of patient-derived tumor organoids (PDTOs) in predicting treatment responses for patients with advanced solid tumors.

Background

Cancer remains a leading cause of morbidity and mortality worldwide, with many patients facing treatment resistance and limited options. The development of reliable in vitro models for drug sensitivity prediction is crucial for advancing personalized medicine. PDTOs offer a promising approach by retaining the biological characteristics of original tumors.

Data Highlights

Key Findings

• PDTOs achieved a 91.5% success rate in establishing organoids from solid tumors.
• Histopathological analysis confirmed that PDTOs recapitulated features of matched original tumors.
• PDTO-based drug sensitivity testing showed an overall accuracy of 85.0% in predicting clinical outcomes.
• The sensitivity and specificity of PDTOs in predicting treatment responses were 86.7% and 80.0%, respectively.
• PDTOs demonstrated potential in overcoming multidrug resistance in advanced solid tumors.

Clinical Implications

The findings indicate that PDTOs may serve as a tool for predicting treatment responses in patients with advanced solid tumors.

Conclusion

This study demonstrates the potential of PDTOs for predicting treatment responses in patients with advanced solid tumors.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report
2. Frontiers in Oncology, 2026 -- Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids
3. Frontiers in Medicine, 2026 -- Editorial: Innovative organoid co-culture systems for enhanced precision medicine in cancer and beyond
4. Acta Neuropathologica -- Organoids and Orthotopic Xenografts from Primary and Recurrent Gliomas Serve as Effective Patient Models for Tailored Oncology Approaches
5. SPECIAL ARTICLE -- ESMO precision oncology working group recommendations
6. Expert consensus on the establishment and clinical application of patient-derived endometrial cancer organoids
7. Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy - PubMed
8. SPECIAL ARTICLE
9. Expert consensus on the establishment and clinical application of patient-derived endometrial cancer organoids
10. Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy - PubMed
11. Integration and validation of complementary ex vivo assays for functional precision oncology - PMC
12. A Pan-Cancer Ex Vivo Drug Screen Atlas for Functional Precision Oncology - PubMed